CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Werr L, Plenker D, Dammert MA, Lorenz C, et al. Mol Cancer Ther 2022;21:821-830.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Werr L, Plenker D, Dammert MA, Lorenz C, et al. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Mol Cancer Ther 2022;21:821-830.
PMID: 35247925